BRAF and melanoma: Advanced melanoma patients carrying a V600 B-RAF mutation are the only cases for which the Food and Drug Administration (FDA) has approved MAPK inhibitors as treatment (https://www.fda.gov/drugs, last accessed on 27 July 2023).